GRI Bio Inc(GRI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -43.74 | Insider Own | - | Shs Outstand | 2.2M | Perf Week | -17.03% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 48.65% | Insider Trans | - | Shs Float | - | Perf Month | -2.56% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.84 | Inst Own | 4.28% | Short Float | - | Perf Quarter | -17.75% |
| Income | -0.01B | P/S | - | EPS this Y | 96.8% | Inst Trans | 230.84% | Short Ratio | 0.34 | Perf Half Y | -34.93% |
| Sales | 0.00B | P/B | 0.4 | EPS next 5Y | 88.82% | ROA | -113.27% | Short Interest | 0.12M | Perf YTD | -72.51% |
| Book/sh | 4.7 | P/C | 0.38 | EPS past 3/5Y | 97.03% 83.24% | ROE | -142.02% | 52W High | -97.64% ($80.36) | Perf Year | -96.69% |
| Cash/sh | 5.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | -93.96% | 52W Low | 39.71% ($1.36) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 93.96% | Gross Margin | - | Volatility(W/M) | 26.68% 13.22% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.3 | EPS Q/Q | 97.52% | Profit Margin | - | RSI (14) | 49.86 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.3 | Sales Q/Q | - | SMA20 | -1.17% ($1.92) | Beta | -1.21 | Target Price | $18.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/19 | SMA50 | 9.45% ($1.74) | Rel Volume | 0.38 | Prev Close | $1.94 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 23.85% - | SMA200 | -68.83% ($6.1) | Avg Volume(3M) | 0.34M | Price | $1.9 |
| IPO | 2021/2/10 | Option/Short | No/Yes | Trades | 539 | Volume | 131,655 | Change | -2.06% |
Company
GRI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 GRI Bio is a clinical-stage U.S. biotech company working to modulate the activity of NKT (natural killer T) cells in order to halt the progression of inflammatory, fibrotic, and autoimmune diseases. Its lead candidate, GRI-0621, is an oral iNKT cell activity inhibitor that met both primary and secondary endpoints in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF). The company is also developing a follow-on pipeline candidate, a dNKT-acting agent, for systemic lupus erythematosus.
Over the past 1 year, on the lower side
98% below its 1-year high.
GRI has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +96.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -100.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 4.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GRID 11.8B
DBC 2.0B
DBA 1.5B
CERY 1.2B
MOO 1.2BIt ranks #4 in the industry
Based on market cap of $4M.
GRI $4M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is GRI?
GRI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GRI?
The market cap of GRI is approximately $4M, ranking 5,730 within its sector.
What is the 52-week high and low for GRI?
GRI has recorded a 52-week high of $80.36 and a low of $1.36.
